Cydan Sets the Pace for Rare Disease R&D

Featured

As part of our ongoing interest in rare disease R&D, we interviewed Niels Svenstrup, the Senior Vice President of Development at Cydan, a virtual rare disease accelerator focused on the development of treatments for rare genetic disorders.

Tune in to hear discussion on Cydan’s unique disease –agnostic model and their prosperous child orphan drug companies, Imara and Tiburio. Gain insight into the future of rare disease R&D, Cydan’s essential collaborations, and more. We invite you to watch now.

Subscribe to WXPress

Receive our newsletter and information on upcoming events.